Sreekanth Pentlavalli
Peptrix
Dr. Sreekanth Pentlavalli is a pharmaceutical scientist, academic entrepreneur, and co-founder of Peptrix, a next-generation skincare company specializing in drug delivery, biomaterials, and peptidomimetic technologies. A Lecturer in Drug Delivery at the University of Bradford, he brings over two decades of research experience spanning injectable hydrogels, transdermal systems, and green chemistry.
As an EPSRC and Wellcome Trust Fellow at Queen's University Belfast, Sreekanth developed long-acting drug delivery platforms for HIV prevention with ViiV Healthcare. He is among the few global researchers with expertise in high-purity peptidomimetics synthesis and holds patents, including peptidomimetics-peptide hydrogel systems.
Sreekanth has published extensively (h-index: 23) and is a Fellow of the Higher Education Academy. Bridging academic innovation with commercial applications, he is developing the world’s first peptidomimetics-based skincare delivery system targeting billion-pound global markets.
About the Enterprise
Millions suffer from skin pigmentation disorders (melasma, vitiligo) with devastating psychosocial impacts. Current treatments have poor efficacy due to limited skin penetration and unstable active ingredients, leading to low patient compliance and inadequate results.
·Peptrix has developed the world's first peptidomimetics-based transdermal skincare delivery system. This innovation combines novel peptidomimetics biomaterials—which resist degradation unlike natural peptides—with dissolvable microneedles. This painless system delivers stable, targeted treatment directly to melanocytes, addressing several skin disorders.
Within 5-10 years, Peptrix will become the leading provider of peptidomimetics-based dermatological treatments, improving quality of life for millions globally while establishing peptidomimetics-microneedle technology as the gold standard for transdermal therapeutic delivery across multiple medical applications.
Achievements
& Highlights
-
30+ peer-reviewed publications (h-index: 23), EPSRC and Wellcome Trust Fellowship awards, collaborations with ViiV Healthcare.
​
-
Proof-of-concept validated – Successfully synthesized sequences with superior stability vs. natural peptides
​
-
Validated technology platform – SelfGel system has proven transdermal delivery success.
Contact
Got an idea, question, or collaboration in mind? Let’s connect.
